Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Treatment-related early discontinuations and adverse events among newly diagnosed people living... BackgroundCohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in the first year following initiation among treatment-naïve people living with HIV (PLWH).MethodsNewly diagnosed PLWH initiating raltegravir, elvitegravir/cobicistat, dolutegravir or bictegravir in combination with emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil fumarate between 10/2007 and 1/2020 at the Orlando Immunology Center were included. Unadjusted incidence rates (IRs) and incidence rate ratios (IRRs) were calculated for treatment-related discontinuations and AEs associated with the initial INSTI in the first year following initiation.ResultsOf 331 enrolled, 26 (8%) initiated raltegravir, 151 (46%) initiated elvitegravir/cobicistat, 74 (22%) initiated dolutegravir and 80 (24%) initiated bictegravir. Within the first year, treatment-related discontinuations occurred in 3 on elvitegravir/cobicistat (IR 0.02 per person-years (PPY)) and 5 on dolutegravir (IR 0.08 PPY); no treatment-related discontinuations occurred among those initiating raltegravir or bictegravir. Eleven treatment-related AEs occurred in 7 on raltegravir (IR 0.46 PPY), 100 treatment-related AEs occurred in 63 on elvitegravir/cobicistat (IR 0.72 PPY), 66 treatment-related AEs occurred in 37 on dolutegravir (IR 0.97 PPY) and 65 treatment-related AEs occurred in 34 on bictegravir (IR 0.88 PPY). Unadjusted IRRs did not reveal any significant difference between INSTIs in terms of early treatment-related discontinuations or AEs.ConclusionsIn our cohort, treatment-related AEs occurred in 43% initiating INSTIs but were responsible for early discontinuation in only 2% with no treatment-related discontinuations observed among those initiating RAL or BIC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antiviral Therapy SAGE

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Download PDF
5 pages

Loading next page...
 
/lp/sage/treatment-related-early-discontinuations-and-adverse-events-among-bAFXlNJqSb
Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
1359-6535
eISSN
2040-2058
DOI
10.1177/13596535231163703
Publisher site
See Article on Publisher Site

Abstract

BackgroundCohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in the first year following initiation among treatment-naïve people living with HIV (PLWH).MethodsNewly diagnosed PLWH initiating raltegravir, elvitegravir/cobicistat, dolutegravir or bictegravir in combination with emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil fumarate between 10/2007 and 1/2020 at the Orlando Immunology Center were included. Unadjusted incidence rates (IRs) and incidence rate ratios (IRRs) were calculated for treatment-related discontinuations and AEs associated with the initial INSTI in the first year following initiation.ResultsOf 331 enrolled, 26 (8%) initiated raltegravir, 151 (46%) initiated elvitegravir/cobicistat, 74 (22%) initiated dolutegravir and 80 (24%) initiated bictegravir. Within the first year, treatment-related discontinuations occurred in 3 on elvitegravir/cobicistat (IR 0.02 per person-years (PPY)) and 5 on dolutegravir (IR 0.08 PPY); no treatment-related discontinuations occurred among those initiating raltegravir or bictegravir. Eleven treatment-related AEs occurred in 7 on raltegravir (IR 0.46 PPY), 100 treatment-related AEs occurred in 63 on elvitegravir/cobicistat (IR 0.72 PPY), 66 treatment-related AEs occurred in 37 on dolutegravir (IR 0.97 PPY) and 65 treatment-related AEs occurred in 34 on bictegravir (IR 0.88 PPY). Unadjusted IRRs did not reveal any significant difference between INSTIs in terms of early treatment-related discontinuations or AEs.ConclusionsIn our cohort, treatment-related AEs occurred in 43% initiating INSTIs but were responsible for early discontinuation in only 2% with no treatment-related discontinuations observed among those initiating RAL or BIC.

Journal

Antiviral Therapy – SAGE

Published: Apr 25, 2023

Keywords: INSTI discontinuations; adverse events; real-world; safety; tolerability

References

  • Update on adverse effects of HIV integrase inhibitors
    Kolakowska, A; Maresca, AF; Collins, IJ
  • Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect
    Yombi, JC
  • Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
    Llibre, JM; Montoliu, A; Miro, JM
  • Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
    Cuzin, L; Pugliese, P; Katlama, C
  • Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
    Hoffmann, C; Welz, T; Sabranski, M
  • Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors
    Hoffmann, C; Llibre, JM
  • Advanced HIV infection in treatment-naive individuals: effectiveness and persistence of recommended 3-drug regimens
    Mounzer, K; Brunet, L; Fusco, JS
  • Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
    Ambrosioni, J.; Rojas Lievano, J; Berrocal, L
  • Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice
    Hoffmann, C.; Schewe, K; Fenske, S
  • Adverse drug reactions to integrase strand transfer inhibitors
    Lepik, KJ; Yip, B; Ulloa, AC
  • Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients
    Palella, FJ; Chmiel, JS; Moorman, AC
  • Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
  • Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines
    Moure, R; Domingo, P; Gallego-Escuredo, JM
  • Bone loss in HIV infection
    Moran, CA; Weitzmann, MN; Ofotokun, I